Skip to main content
OpenTrials
Completed

NCT Number: NCT02117687

A Safety and Efficacy Study of OPTIVE FUSION™ With VISMED® Multi for the Management of Dry Eye

This study will evaluate the safety and efficacy of OPTIVE FUSION™ compared to VISMED® Multi for the management of dry eye.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

Paris, France

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Use of artificial tears for dry eye in both eyes for at least 3 months
  • Use of preservative-free artificial tears at least twice daily for 2 weeks;

Exclusion criteria

  • Cataract, laser-assisted in situ keratomileusis (LASIK), photorefractive keratectomy (PRK) surgery in the last 12 months
  • Use of punctal plugs or contact lenses in the last month
  • Active ocular allergy within last 2 years
  • Best corrected visual acuity (BCVA) less than 20/200 in either eye

Treatment and study plan

carboxymethylcellulose 0.5%/glycerin 0.9%

Drug

1-2 drops OPTIVE FUSION™ (carboxymethylcellulose 0.5%/glycerin 0.9%) in each eye as needed at least 2 times and no more than 6 times daily, for 3 months.

Other names: OPTIVE FUSION™

sodium hyaluronate 0.18%

Drug

1-2 drops VISMED® Multi (sodium hyaluronate 0.18%) in each eye as needed at least 2 times and no more than 6 times daily, for 3 months.

Other names: VISMED® Multi

Primary outcomes

  1. Change From Baseline in Global Ocular Staining Score in the Study Eye

    Time frame: Baseline, Day 35

    Global ocular staining of the study eye was graded from 0 to 15 and was the sum of corneal fluorescein staining severity, nasal conjunctiva lissamine green staining severity, and temporal conjunctiva lissamine green staining severity. Staining of the cornea followed ocular administration of fluorescein dye and was graded on a 6-point scale (0=no staining to 5=diffuse staining). Staining of the conjunctiva followed ocular administration of lissamine green dye and was graded on a 6-point scale (0=no staining to 5=diffuse staining). Conjunctival staining was evaluated in two zones, nasal and temporal.

Secondary outcomes

  1. Change From Baseline in Global Ocular Staining Score in the Study Eye

    Time frame: Baseline, Month 3

    Global ocular staining of the study eye was graded from 0 to 15 and was the sum of corneal fluorescein staining severity, nasal conjunctiva lissamine green staining severity, and temporal conjunctiva lissamine green staining severity. Staining of the cornea followed ocular administration of fluorescein dye and was graded on a 6-point scale (0=no staining to 5=diffuse staining). Staining of the conjunctiva followed ocular administration of lissamine green dye and was graded on a 6-point scale (0=no staining to 5=diffuse staining). Conjunctival staining was evaluated in two zones, nasal and temporal.

  2. Change From Baseline in Ocular Surface Disease Index© (OSDI) Score

    Time frame: Baseline, Day 35

    The OSDI is a 12-question survey for patients to document their dry eye disease symptoms on a 5-point scale (0=none of the time and 4=all of the time). Higher scores represent greater disability. Scores are totaled over the 12 questions and converted to a score of 0-100 (0=no disability and 100=complete disability). A negative number change from baseline represents an improvement and a positive number change from baseline represents a worsening.

  3. Change From Baseline in the Schirmer Test in the Study Eye

    Time frame: Baseline, Day 35

    The Schirmer's Test measures the rate of secretion of tears produced by the study eye over 5 minutes. The results indicate the presence of dry eye (Normal = greater than or equal to 10 millimeters (mm) of tears, Dry Eye = less than 10 mm of tears). The smaller the number, the more severe the dry eye. A positive number change from baseline indicates an increase in tears (improvement) and a negative number change from baseline indicates a decrease in tears (worsening).

  4. Subject Assessment of Dry Eye Symptoms on a 5-Point Scale

    Time frame: Baseline, Day 35, Month 3

    Subjects assess dry eye symptoms on a 5-point scale (none, mild, moderate, severe, very severe).

  5. Subject Global Assessment of Treatment Efficacy on a 5-Point Scale

    Time frame: Baseline, Day 35, Month 3

    Subjects assess global treatment efficacy compared to baseline on a 5-point scale (much worse, worse, about the same, improved, much improved).

  6. Subject Assessment of Treatment Acceptability on a 5-Point Scale

    Time frame: Day 35

    Subjects assess treatment acceptability (likability and comfort) on a 5-point scale (strongly agree, agree, neither agree nor disagree, disagree, strongly disagree).

  7. Investigator Global Assessment of Treatment Efficacy on a 4-Point Scale

    Time frame: Day 35, Month 3

    Investigators assess global treatment efficacy on a 4-point scale (very satisfactory, satisfactory, poor, very poor).

  8. Change From Baseline in Tear Break-up Time (TBUT) in the Study Eye

    Time frame: Baseline, Day 35

    TBUT is the time required for dry spots to appear on the surface of the eye after blinking in the worse eye. The longer it takes, the more stable the tear film. A short TBUT is a sign of poor tear film. A positive number change from baseline indicates an increase in TBUT (improvement) and a negative number change from baseline indicates a decrease in TBUT (worsening).

  9. Work Productivity and Activity Impairment Questionnaire Score

    Time frame: Baseline, Day 35, Month 3

    The Work Productivity and Activity questionnaire assesses the effect of dry eye on the ability of subjects to work and perform regular activities on a scale from 0 to 10 during the past 7 days (0=dry eye had no effect on my work/daily activities to 10=dry eye completely prevented me from working/doing my daily activities). Since not all subjects were in full time employment during the study, not all items of the questionnaire were applicable to all subjects at each visit. Outcomes are expressed as impairment percentages, with higher numbers indicating greater impairment and less productivity.

  10. Change From Baseline in Corneal Staining in the Study Eye

    Time frame: Baseline, Day 35, Month 3

    The cornea is the transparent front part of the eye which covers the iris and pupil. Staining of the cornea followed ocular administration of fluorescein dye and was graded on a 6-point scale (0=no staining to 5=diffuse staining). A negative number change from baseline represents a decrease in corneal staining (improvement) and a positive number change from baseline represents an increase in corneal staining (worsening).

  11. Change From Baseline in Conjunctival Staining in the Study Eye

    Time frame: Baseline, Day 35, Month 3

    The conjunctiva is the clear membrane covering the white surface of the eye. Staining of the conjunctiva followed ocular administration of lissamine green dye and was graded on a 6-point scale (0=no staining to 5=diffuse staining) in the temporal and nasal locations. A negative number change from baseline represents a decrease in corneal staining (improvement) and a positive number change from baseline represents an increase in corneal staining (worsening).

  12. Conjunctival Hyperaemia in the Study Eye

    Time frame: Baseline, Day 35, Month 3

    Macroscopic conjunctival hyperemia (eye redness) is graded in the study eye on a 5-point scale (none, trace, mild, moderate, severe).

  13. Study Product Use

    Time frame: Day 8, Day 35, Month 3

    The number of times the study product is administered per day is recorded.

Sponsors and collaborators

Lead sponsor

Allergan

Industry

Registry information

Important dates

Study start
2014
Primary completion
2015
Study completion
2015
First posted
Apr 21, 2014
Registry last updated
Apr 18, 2019

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.